Bone Support

Share Price

  • Contact Us
Follow
  • US site
    • Global English Site
    • US site
    • Global Swedish Site
  • Bonesupport
    • Message from the CEO
    • Vision & Mission
    • Sustainability
    • History
    • Management
    • The Board
    • Our Partners
    • Careers
  • Products
    • CERAMENT® G with Gentamicin
    • CERAMENT® BONE VOID FILLER
    • Delivery Devices for CERAMENT®
  • Innovation
    • Pipeline
    • CERTiFy Clinical Trial
  • Medical Professionals
    • TRAUMA: WHY USE CERAMENT®
    • BENIGN BONE TUMORS: WHY USE CERAMENT®
    • REVISION ARTHROPLASTY: WHY USE CERAMENT®
    • FOOT AND ANKLE: WHY USE CERAMENT®
    • CERAMENT® G Reimbursement
  • Investors
    • Financials
    • Financial Reports
    • Presentations
    • The Share
    • Shareholders
    • Analyst Coverage
    • Corporate Governance
    • Calendar
    • Q&A
    • Definitions
  • Patients
    • Bone Grafts
    • BONE DEFECTS CAUSED BY TRAUMA
    • BONE DEFECTS CAUSED BY BENIGN BONE TUMORS
    • BONE DEFECTS CAUSED BY HIP AND KNEE REVISIONS
  • Events
  • Media
    • Press Releases
    • Publications and Resources
    • Multimedia
  • Contact Us
  • Global English Site
  • US site
  • Global Swedish Site
  • Financials
  • Financial Reports
  • Presentations
  • The Share
  • Shareholders
  • Analyst Coverage
  • Corporate Governance
  • Calendar
  • Q&A
  • Definitions
  • CAPITAL MARKETS DAY 2022

Other Reports

BONESUPPORT HOLDING AB was listed on Nasdaq Stockholm on 21st June 2017 and interim reports are published from Q2 2017.

PDF Icon

Prospectus 2017

11/06/2017

©BONESUPPORT AB 2023. ALL RIGHTS RESERVED. CERAMENT and BONESUPPORT are registered Trademarks of BONESUPPORT AB.

  • Home
  • Contact Us
  • Privacy Policy
  • Cookie Policy